JSSH
BDTX icon

J. Safra Sarasin Holding’s Black Diamond Therapeutics BDTX Stock Holding History

J. Safra Sarasin Holding’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.7K Buy
+15,500
New +$37.9K ﹤0.01% 792

Other funds holding BDTX

DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
BCM
Brookstone Capital Management Wheaton, Illinois $9.99B AUM 23.61% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

J. Safra Sarasin Holding's BDTX Position: Q2 2026 in Review

J. Safra Sarasin Holding opened a new position in Black Diamond Therapeutics (BDTX) in Q2 2026: 15,500 shares worth $28.7K. The stake represents ﹤0.01% of the portfolio and ranks #792 among its holdings.

13 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • J. Safra Sarasin Holding held 15,500 shares of Black Diamond Therapeutics worth $28.7K as of Q2 2026.
  • Black Diamond Therapeutics was a new J. Safra Sarasin Holding position in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #792 holding.
  • 13 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.